Genmab — April 2021

Sukkeralf

Roche publicerer nye sklerosedata for at holde Novartis fra døren

Med den nyligt godkendte sklerosemedicin Kesimpta - oprindeligt udviklet af Genmab - er Novartis i fuld gang med at lange ud efter Roches dominerende lægemiddel på markedet, og nu prøver Roche at slå igen.

(medwatch.dk)

Helge_LarsenPI-redaktør

Langers Skarpe: Deltag i festen, men undgå tømmermænd og forlad den i tide

Just a moment...

(www.proinvestor.com)

E_L

Health Canada-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis / Dara https://www.newswire.ca/news-releases/darzalex-r-sc-becomes-the-first-and-only-health-canada-approved-treatment-for-patients-with-newly-diagnosed-light-chain-al-amyloidosis-a-rare-disease-849615211.html

E_L

CEO Jan van de Winkel rykker op på førstepladsen i Økonomisk Ugebrevs årlige CEO Performance-ranking. https://ugebrev.dk/ledelse/genmab-vinder-ceo-performance-redningsplan-blev-succes/

E_L

waiting for this, New trial - A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab https://clinicaltrials.gov/ct2/show/NCT04847596

Bulder

yes, pretty important these days

E_L

These results obtained after 12 months of maintenance therapy reveal the potential of D-VRd and D-R maintenance as a new treatment for patients with NDMM who are eligible for transplant.
https://multiplemyelomahub.com/medical-information/daratumumab-plus-vrd-vs-vrd-in-newly-diagnosed-mm-griffin-trial-updated-analysis

E_L

i expect this to be an area we will hear a lot more about , Dara maintanenance, we should be getting more and more data there. Also hope we will get some smoldering data soon. Next areas of expansion.

Sukkeralf

Just a moment...

(www.firstwordpharma.com)

Sukkeralf

DARZALEX SC Becomes the First and Only Health Canada-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis, A Rare Disease